Skip to main content

Table 1 Clinical characteristics at the first study visit in 435 children in the Nordic juvenile idiopathic arthritis (JIA) cohort according to the presence of acute or chronic uveitis during > 7 years of follow-up

From: Incidence and predictors of Uveitis in juvenile idiopathic arthritis in a Nordic long-term cohort study

 

All children

No uveitis

Acute uveitis

Chronic uveitis

N

 

N

 

N

 

N

 

Female gender

435

286 (65.8)

346

227 (65.6)

9

4 (44.4)

80

55 (68.8)

Age at onset, median (1st, 3rd q)

435

5.5 (2.4, 9.5)

346

6.2 (2.8, 10)

9

10.8 (9.3, 12.9)

80

3.2 (1.8, 5.9)

Oligoarticular onseta

435

224 (51.5)

346

180 (52.0)

9

1 (11.1)

80

43 (53.8)

ANA positive

427

116 (27.2)

340

79 (23.2)

9

0 (0)

78

37 (47.4)

AHA >15 U/ml

134

23 (17.2)

112

14 (12.5)

3

1 (33.3)

19

8 (42.1)

RF positive

424

10 (2.4)

336

9 (2.7)

9

1 (11.1)

79

0 (0.0)

HLA-B27 positive

413

87 (21.1)

325

62 (19.1)

9

7 (77.8)

79

18 (22.8)

ESR, median (1st, 3rd q)

354

14 (8, 28)

276

14 (8, 26)

8

23 (10, 41)

70

16 (9, 36)

CRP, median (1st, 3rd q)

350

0 (0, 10)

276

0 (0, 10)

9

0 (0, 16)

65

0 (0, 14)

JADAS27, median (1st, 3rd q)

194

5.1 (2.0, 11.0)

157

5.0 (2.0, 9.8)

7

10.4 (5.6, 14.9)

30

3.8 (1.6, 12.5)

CHAQ, median (1st, 3rd q))

273

0.3 (0.0, 1.0)

222

0.4 (0.0, 1.0)

8

0.4 (0.1, 1.2)

43

0.3 (0.0, 1.0)

DMARD use 2nd visitb

350

125 (35.6)

316

111 (35.1)

7

3 (37.5)

27

11 (42.3)

  1. Data are presented as numbers (%), unless otherwise noted
  2. ANA antinuclear antibodies measured by immunofluorescence on Hep-2 cells, and RF rheumatoid factor; two positive tests taken > 3 months apart in participants with one or more tests taken, AHA > 15 U/ml antihistone antibodies IgM/IgG >15 U/ml, HLA-B27 human leucocyte antigen B27, Age at onset age at onset of arthritis in years, ESR erythrocyte sedimentation rate, CRP C-reactive protein JADAS27 Juvenile arthritis disease activity score based on 27 joint count, CHAQ Child health assessment questionnaire
  3. aOligoarticular JIA 6 months after disease onset, according to the International League of Associations for Rheumatology (ILAR) classification criteria. [25]
  4. bPercentage of DMARD = Disease modifying anti-rheumatic drugs including biological agents used within the 2nd visit (median 13 months (IQR 12–14)) in 350 children without uveitis at the time of the 2nd study visit, differentiating into no uveitis, acute, or chronic uveitis during further follow-up